Why Is ODYSSEY THERAPEUTICS (ODTX) Stock Moving Today?

Why ODTX stock is up today

Odyssey Therapeutics (ODTX) surged 9.69% to $25.36 in a single session, driven by a combination of recent analyst coverage and upcoming company appearances at key industry events. The stock opened with a 1.5% gap up and reached a session high of $25.55 before closing near that level. The move reflects growing investor attention following a series of analyst actions and the company’s participation in two major healthcare conferences.

What Happened

The stock’s sharp rise comes after HC Wainwright & Co. initiated coverage on Odyssey Therapeutics with a Buy rating and a $44 price target. This was followed by JP Morgan raising its price target to $29 and maintaining an Overweight rating. Oppenheimer also reiterated its Outperform rating with a $40 price target. These analyst actions have contributed to renewed investor optimism. Additionally, Odyssey Therapeutics is scheduled to present at the Morgan Stanley 24th Annual Global Healthcare Conference and the Stifel 2026 Virtual Immunology and Inflammation Forum. These events provide the company with a platform to highlight its autoimmune and inflammatory disease programs, including its collaboration with Evotec’s AI-driven discovery platform.

What The Data Shows

The stock’s intraday performance shows a strong upward bias, with volume reaching 0.0M shares traded so far. The stock has printed nine fresh 52-week highs on September 17, 2026, indicating sustained buying pressure. Despite the recent rally, the company remains unprofitable, with a trailing twelve-month (TTM) revenue decline of 33.5% and an EPS of -14.05. The market cap is currently $1.1B, and the stock is trading within its 52-week range of $15.10 to $29.05.

What To Watch

Investors should monitor the company’s presentations at the upcoming Morgan Stanley and Stifel conferences for further insights into its pipeline and strategic direction. The stock’s ability to sustain its recent momentum will depend on continued analyst support and positive developments in its clinical programs.